The long-standing belief that multinodular goiters are associated with a lower risk of developing into carcinoma has been challenged by the results of some recent studies. In addition, we have noticed in our practice that a sizable proportion of cancers have been arising from nondominant nodules. We performed a retrospective study of 223 cases to determine (1) the incidence of carcinoma in multinodular goiters that required surgical management in our local, predominantly Asian population and (2) the incidence of carcinoma arising from nondominant nodules. We reviewed the records of all patients with a multinodular goiter who had undergone a thyroidectomy over a period of more than 10 years in our Department of Otolaryngology-Head and Neck Surgery. We examined the histopathology reports for (1) the presence of carcinoma, (2) whether the carcinoma was isolated/unifocal or multifocal, (3) the histologic type of cancer, and (4) whether the isolated/unifocal cancers arose from the dominant or nondominant nodule. Our study population was made up of 47 males and 176 females, aged 15 to 90 years (mean: 53). We found that the incidence of malignancy in surgically treated multinodular goiters was 14.3% (32 of 223 patients). Of the 32 malignancies, 18 (56.3%) were isolated/unifocal and 14 (43.8%) were multifocal. In the isolated/unifocal group, 9 malignancies (50.0%) arose from nondominant nodules and 8 (44.4%) from dominant nodules; in the remaining case, the nodule of origin could not be determined. Our findings corroborate those in the recent literature in that the risk of malignancy associated with multinodular goiters is comparable to that of single thyroid nodules.
Introduction
Multinodular goiter is a relatively common thyroid disorder with a prevalence of 4 to 7% worldwide. [1] [2] [3] [4] Risk factors include black race, obesity, increasing age, iodine deficiency, a history of irradiation, and female sex. 5, 6 Traditionally, patients with multinodular goiter have been considered to have a lower risk of malignancy than those with a single nodule. 3 It was initially believed that solitary nodules carry a higher predilection for neoplastic change, while the presence of multiple nodules suggested that there were only colloid nodular changes with little if any predisposition for malignancy. 7 However, some published studies have challenged that thinking, their results suggesting that the incidence of cancer in multinodular goiter is actually as high as that in single thyroid nodules. 6, [8] [9] [10] Various reports have indicated that the incidence of thyroid carcinoma in multinodular goiter is between 8.6 and 13%. 8, 9 This is a substantial figure, considering that the incidence in solitary cold thyroid nodules, as reported by McCall et al, is 17%. 8 Moreover, the focus of investigation has mostly been on dominant nodules; few studies have addressed the incidence of cancer in nondominant nodules. 11 In this article, we describe our study of carcinoma in multinodular goiters and compare its incidence in dominant and nondominant nodules.
Patients and methods
We performed a retrospective study of 223 patients-47 males and 176 females, aged 15 to 90 years (mean: 53), most of whom were Asian-with a multinodular goiter who had undergone a thyroidectomy over a period of more than 10 years in our Department of Otolaryngology-Head and Neck Surgery. Our goals were (1) to determine the incidence of carcinoma in multinodular goiters that necessitated surgical resection and (2) to compare the incidence of carcinoma arising in dominant and nondominant nodules.
The multinodular goiters in our population had been diagnosed on the basis of either clinical palpation or an ultrasonographic finding of two or more thyroid nodules. The indication for surgery in 201 patients (90.1%) was a preoperative clinical suspicion of a possible malignancy; in the remaining 22 patients (9.9%), the indication was some other finding (i.e., to alleviate compression symptoms or to control thyrotoxicosis).
Patients had undergone either a hemithyroidectomy, a subtotal thyroidectomy, or a total thyroidectomy based on pre-and intraoperative findings. All specimens had been sent for histopathologic examination.
We examined the final histopathology reports for (1) the presence of carcinoma, (2) whether the carcinoma was isolated/unifocal or multifocal, (3) the histologic type of cancer, and (4) whether the isolated/unifocal cancers arose from the dominant or nondominant nodule.
Institutional Review Board and Ethics Committee approval was granted by the National Healthcare Group's Research and Development Office in Singapore.
Results

Presence of carcinoma.
Of the 223 patients, carcinoma was confirmed on final postoperative histopathology in 32 patients (14.3%).
Of the 32 patients with a histologically proven malignancy after surgery, 14 (43.8%) had undergone a hemithyroidectomy without a completion thyroidectomy, 10 (31.3%) had undergone a total thyroidectomy as their primary surgery, and 8 (25.0%) had undergone a hemithyroidectomy followed by a completion thyroidectomy. The 14 patients who had undergone a hemithyroidectomy without completion thyroidectomy had been treated that way because their preoperative histology had indicated a papillary microcarcinoma.
All 32 malignancies occurred in the group of 201 patients who had undergone surgery on the basis of a preoperative suspicion of cancer (15.9%); none was found in the 22 patients who had undergone surgery for an indication other than suspected cancer (figure 1).
Unifocal vs. multifocal. Of the 32 malignancies, 18 (56.3%) were isolated/unifocal and 14 (43.8%) were mul-tifocal (figure 2). We were unable to tabulate the number of malignant nodules in the 14 patients with multifocal disease because this information was not consistently captured in our patients' histopathology reports.
Histology. As expected, all 14 cases of multifocal cancer were identified as papillary thyroid carcinomas, which is characteristic of this particular histologic subtype. Papillary carcinoma was also the main histopathologic subtype in the patients with unifocal cancer, occurring in 17 of 18 patients (94.4%); the other patient (5.6%) had follicular carcinoma.
Dominant vs. nondominant nodule. Of the 18 unifocal carcinomas, 8 (44.4%) occurred in the dominant nodule and 9 (50.0%) in the nondominant nodule; in the remaining patient (5.6%), the nodule of origin could not be determined ( figure 2) . Overall, the incidence of carcinoma arising from the nondominant nodule in patients with surgically treated multinodular goiter was 4.0% (9 of 223 patients), and the incidence of carcinoma arising from the dominant nodule was 3.6% (8 of 223).
Discussion
The etiology and pathophysiology of multinodular goiter is believed to involve a combination of primary and secondary factors. Primary factors include the genetic heterogeneity of normal follicular cells and the acquisition of new inheritable qualities by replicating epithelial cells. Secondary factors include an elevated thyroid-stimulating hormone level, iodine insufficiency, and inborn errors of thyroid hormone synthesis. 12 In the past, it was believed that multinodularity was a marker for benign thyroid disease. 7 However, Figure 1 . Flowchart shows the characteristics of our study population. yONg, LOh, PETERSSON, ThONg most published literature since then has found that the incidence of malignancy arising a multinodular goiter is also notable, ranging from 7.5 to 21.2%. 6, 9, 13, 14 The incidence appears to be similar to that of solitary thyroid nodules. 10 Our finding that the overall incidence of cancer in multinodular goiter patients who had undergone surgery was 14.3% is comparable to that reported in other studies around the world. The incidence of cancer varied depending on the indication of surgery-15.9% for those who had undergone surgery for a suspected malignancy and 0% for those who had undergone surgery for other indications.
Given that (1) the incidence of malignancy in multinodular goiter is noteworthy and (2) there are numerous nodules in multinodular goiter, we must ask ourselves, Which nodules should we as clinicians focus our attention and evaluation efforts on? Should we focus on only the largest, dominant nodules, or should we evaluate all the nodules equally despite the attendant increase in cost?
Currently, it is widespread practice that physicians concentrate their attention on the dominant nodules while paying scant attention to the other, smaller nodules during the clinical evaluation and follow-up of multinodular goiter. 15 However, supporting evidence for this practice is conflicting. Frates et al 16 found that the incidence of cancer in the dominant nodule was 72.5%, and Paksoy et al 17 reported 64.2%. On the other hand, Erbil et al found that 59% of thyroid cancer foci lay within the nondominant nodule and 41% within the dominant nodule. 18 We found that the incidence of carcinoma arising from the nondominant nodule was 50.0%, which was similar to the incidence in the dominant nodule (44.4%).
We believe that this finding serves as a timely reminder to clinicians to assess nondominant nodules, even the small nodules, with the same care as dominant nodules during ultrasound and to perform fine-needle aspiration cytology accordingly.
Our experience supports the recommendation in the most recent American Thyroid Association guidelines 6 that all thyroid nodules larger than 1 cm should be evaluated and that all nodules that exhibit suspicious ultrasonographic features should be aspirated and sent for cytology.
To calculate the overall incidence of cancer in multinodular goiter would require that all patients with multinodular goiter be assessed, regardless of whether surgery is necessary. Unfortunately, as is the case with most tertiary care surgical centers, our endocrinology colleagues usually refer to us only those patients with multinodular goiter who have a clinical suspicion of cancer or a large enough goiter to cause compression or cosmetic issues. A sizable number of patients with multinodular goiter are not referred to us, and they are therefore unavailable for our assessment.
In our study, we evaluated the incidence of cancer in multinodular goiter only in patients who required surgery. Although our data collection might have been biased in terms of our examination of only a surgical population, we believe that our findings are still applicable because they are representative of a typical patient population seen in a surgical practice. Our results are especially useful for surgeons in terms of preoperative counseling. In addition, by breaking down the incidence of malignancy according to surgical indication (15.9% for suspected malignancy and 0% for other indications), our data provide clinicians with information to counsel each patient more precisely and relevantly.
In conclusion, the incidence of malignancy in multinodular goiter is appreciable, and clinicians should evaluate nodular thyroid disease the same way regardless of whether the patient has a solitary or a multinodular goiter. Moreover, smaller, nondominant nodules should be examined with the same amount of vigilance as are dominant nodules. 
